Skip to Content
Merck
  • Disposition of mephenytoin and its metabolite, nirvanol, in epileptic patients.

Disposition of mephenytoin and its metabolite, nirvanol, in epileptic patients.

Neurology (1984-08-01)
W H Theodore, M E Newmark, B T Desai, H J Kupferberg, J K Penry, R J Porter, W D Yonekawa
ABSTRACT

We investigated the conversion of mephenytoin to nirvanol in five patients with uncontrolled complex partial seizures. After a 50-mg single oral dose, mean peak mephenytoin level was 0.48 microgram/ml and nirvanol 0.37 microgram/ml. After 400 mg, peak mephenytoin level was 3.9 micrograms/ml and nirvanol 2.5 micrograms/ml. On 400 mg daily, mephenytoin reached a mean steady-state level of 1.5 micrograms/ml. Nirvanol mean steady-state level was 18 micrograms/ml. Mean plasma half-life was 17 hours for mephenytoin and 114 hours for nirvanol. Two patients had reduced seizures during mephenytoin therapy and one a transient increase during drug withdrawal. No toxicity was seen, but mephenytoin was not more effective than phenytoin.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(R)-(−)-Nirvanol
Sigma-Aldrich
(S)-(+)-Nirvanol